A gene therapy has successfully delivered dopamine directly into the brain, marking a key developmental milestone. The treatment appears to be aimed at addressing conditions such as a rare childhood disease and Parkinson's disease, with some outlets suggesting it has shown promise in restoring a missing enzyme. The therapy's approval status and potential applications are still being explored, with some treatments reportedly in the clinical trial pipeline.